{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055716","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.370988+00:00","generated_at":"2026-06-28T11:12:40.389531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Achieve Life Sciences Q3 net loss $6.7M; ORCA-2 topline data expected H1 2022","bullets":["Cash equivalents $33.4M; total operating expenses $6.7M for Q3, $26.0M for 9 months.","ORCA-2 Phase 3 completed treatment; topline data expected first half 2022.","ORCA-3 Phase 3 enrollment of ~750 subjects to start by early 2022.","FDA accepted IND for cytisinicline e-cigarette cessation trial; ORCA-V1 to start Q2 2022.","Two U.S. patents issued for 3.0 mg TID dosing regimen, expiring 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055716","json":"https://secwatch.observer/filing/0001564590-21-055716.json","markdown":"https://secwatch.observer/filing/0001564590-21-055716.md","text":"https://secwatch.observer/filing/0001564590-21-055716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459021055716/0001564590-21-055716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459021055716/achv-8k_20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:12:40.389531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}